Eli Lilly and Company

Eli Lilly and Company, often referred to as Lilly, is one of the world's largest pharmaceutical companies and is headquartered in Indianapolis, Indiana, in the United States. As of now, Lilly's shares trade under the ticker symbol "LLY" on the New York Stock Exchange.

Lilly produces a wide range of human pharmaceutical products in key therapeutic areas, including endocrinology, oncology, cardiovascular health and neuroscience. Their workforce research and develop new treatments to meet the world’s evolving health needs. Some of their most well-known products include insulin products like Humulin and Humalog, Cialis for erectile dysfunction, and cancer treatments like Alimta and Verzenio.

Recent years have seen Lilly stay one step ahead of several patent expirations by developing and launching new drugs, which shows promising and successful R&D efforts. This pharmaceutical giant launched a number of significant new products recently, which are driving a massive chunk of their growth.

They have a consistent record of earnings per share growth and the dividend payment has been increasing over the years, making the stock a potential choice for investors looking for both growth and income.

However, Lilly also operates in an industry that faces significant challenges, including potential healthcare reforms, pricing pressures, strong competition, and complex regulatory hurdles. The company's product pipeline, market performance and general industry conditions should be regularly reviewed.

Please remember that investment always contains risks and it's important to do your own research and consider seeking advice from a qualified professional.